AGEN Stock Summary and Trading Ideas (Agenus | NASDAQ:AGEN)

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Agenus trades on the NASDAQ stock market under the symbol AGEN.

As of June 5, 2026, AGEN stock price declined to $3.23 with 420,162 million shares trading.

AGEN has a beta of 2.80, meaning it tends to be more sensitive to market movements. AGEN has a correlation of 0.16 to the broad based SPY ETF.

AGEN has a market cap of $134.51 million. This is considered a Micro Cap stock.

Last quarter Agenus reported $34 million in Revenue and $1.02 earnings per share. This fell short of revenue expectation by $-96 million and missed earnings estimates by -$.81.

In the last 3 years, AGEN traded as high as $42.60 and as low as $1.38.

The top ETF exchange traded funds that AGEN belongs to (by Net Assets): VTI, VXF, IWC.

AGEN has underperformed the market in the last year with a return of -37.4%, while SPY returned +25.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AGEN shares. However, AGEN has outperformed the market in the last 3 month and 2 week periods, returning +10.6% and +3.9%, while SPY returned +8.5% and -1.1%, respectively. This indicates AGEN has been having a stronger performance recently.

AGEN support price is $3.23 and resistance is $3.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGEN shares will trade within this expected range on the day.